Neuralink Co-Founder's Science Corp Secures $400 Million to Expand Brain Tech
Medical technology startup Science Corporation has raised a $400 million Series D funding round, pushing its valuation to $3.5 billion as it develops vision-restoring implants and direct brain interfaces.
🚀Startups & FundingPhoto: TechCrunch AI
Key points
- Science Corporation raised a $400 million Series D funding round, reaching a $3.5 billion valuation.
- The flagship PRIMA chip helps restore vision for age-related macular degeneration and is approved in Europe.
- The company plans to seek US regulatory approval and is designing human trials for neurological conditions like Parkinson's disease.
Science Corporation, a medical technology enterprise established in 2021 by former Neuralink president Max Hodak, has successfully closed a $400 million Series D financing round. According to a person familiar with the transaction, the new capital places the company's valuation at $3.5 billion. The funding round drew participation from prominent backers including Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
The startup's initial commercial offering, named PRIMA, is a wearable and implantable chip designed to assist individuals suffering from age-related macular degeneration in recovering partial vision. The medical device has already secured regulatory approval in Europe and is currently available in Germany. Furthermore, Hodak recently announced that the technology is undergoing clinical trials for Stargardt's disease, another condition that leads to blindness.
With the newly acquired funds, the enterprise intends to introduce the PRIMA device to the United States market by utilizing the FDA’s Humanitarian Device Exemption pathway. This regulatory mechanism permits experimental medical technologies to be deployed for rare conditions, with the startup successfully arguing that advanced bilateral macular degeneration is sufficiently uncommon to qualify.
Beyond vision restoration, Science Corporation is actively pursuing its core objective of bridging silicon with cultured neurons to build direct bio-hybrid brain sensors. The organization is currently collaborating with Yale neurosurgery professor Murat Günel to design initial human trials aimed at exploring potential treatments for Parkinson's disease and other severe neurological injuries.
Source TechCrunch AI — techcrunch.com/2026/11/17/science-corporations-brain-tech-is-worth-3-5-… ↗
Read next
🌐Work & SocietyAmbience Healthcare Expands Clinical AI Suite for Hospital Operations
Ambience Healthcare has launched new AI tools designed to assist hospital staff with patient rounding and discharge planning, aiming to improve both clinical efficiency a…
🧠AI AnalysisAI Models Vulnerable to Manipulation in Simulated Warfare Scenarios, Research Shows
New research reveals that leading AI models from firms like OpenAI and Anthropic can be manipulated into identifying civilian targets when prompted with game scenarios.
⚖️Regulation & PolicyAWS Highlights Enterprise Governance and AI Workspace Quick Ahead of re:Invent 2026
Amazon Web Services is spotlighting its workplace AI platform, AWS Quick, ahead of its upcoming re:Invent 2026 conference, emphasizing secure deployment across major ente…
🏢Big TechLoanPro Integrates Amazon Bedrock to Automate Loan Servicing Workflows
LoanPro has deployed a multi-agent AI assistant using Amazon Bedrock and Anthropic's Claude models to help lenders manage borrower accounts, resulting in a 15% reduction …
🏢Big TechGoogle Brings Wallet App to iOS Users Across the United States
Google has expanded the availability of its Wallet application to iOS devices in the U.S., allowing Apple users to store digital passes, tickets, and receipts.
⚖️Regulation & PolicyMicrosoft Reveals Cause of Global Outlook Outage
A latent software bug caused a nearly 24-hour global outage of Microsoft’s Exchange Online services, affecting millions of users worldwide.